医疗保健股票市场 - 医疗保健股票在2024年有很大的增长空间[1] - 医疗行业因全球对健康和福祉的关注而增长[1] - 医疗股票将再次引起买家的兴趣，因为他们认识到该行业产生巨大利润的潜力[3] Vertex Pharmaceuticals（VRTX） - Vertex Pharmaceuticals（VRTX）在2024年医疗股票市场上取得了重大进展[5] - Vertex Pharmaceuticals在疼痛治疗方面取得了巨大进展[6] - Vertex Pharmaceuticals正在扩大其产品组合，成为2024年医疗股票市场上的重要参与者[7] CRISPR Therapeutics（CRSP） - CRISPR Therapeutics因其开创性的基因治疗工作而备受关注[9] - CRISPR Therapeutics在与Vertex合作开发糖尿病治疗方面取得了重要进展[12] Illumina（ILMN） - Illumina在基因测序方面取得了重大突破，成为2024年医疗股票市场上的重要参与者[13] - Illumina的战略联盟显示了其在医学研究领域的重要性[14] - Illumina在全球医疗模式变革中扮演着重要角色[15]

公司背景 - CRISPR Therapeutics去年股价上涨54%，朝着重要里程碑迈进[1] - CRISPR Therapeutics专注于基因编辑，利用CRISPR技术修复导致某些疾病的有缺陷基因[3] - CRISPR Therapeutics的首个产品获得监管批准，显示监管机构愿意批准CRISPR基因编辑产品，只要临床数据强有力[4]

It finally happened. About 10 years after being created, gene-editing specialist CRISPR Therapeutics (CRSP 1.46%) earned approval for its first therapy late last year. The treatment in question is called Casgevy and targets sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), two blood-related diseases. This regulatory development was a significant milestone for CRISPR, but the biotech will need more clinical and regulatory success in the years ahead to keep investors happy.Can CRISPR ...

With CRISPR Therapeutics (CRSP 5.28%) in the news thanks to its successful work in developing cutting-edge gene therapies, it's easy to assume that everything in the business is going swimmingly. Between the fruits of its ongoing commercialization process and a quickly expanding development pipeline, it's certainly true that it has more than one opportunity at impressing the market and enriching its shareholders.Still, even the most successful companies experience setbacks from time to time, and this biotec ...

Editas Medicine (EDIT -0.98%) and CRISPR Therapeutics (CRSP 1.66%) share more than a few similarities despite being at different stages of the biotech lifecycle. Both companies are betting that their acumen with gene editing will enable them to make therapies that were impossible to conceive of just a few years ago, and they're both aiming for the same disease markets.But as you may have heard, with the recent launch of its first gene therapy, called Casgevy, CRISPR Therapeutics is now a revenue-stage biote ...

CRISPR Therapeutics - CRISPR Therapeutics去年股价上涨了54%，并且最近获得了其首个基因编辑疗法Casgevy的批准，这可能是继续看好这家生物科技公司的理由[3] - 高盛分析师预计Casgevy的收入可能会达到每年39亿美元的峰值，这将极大改善CRISPR的财务前景[4] - CRISPR还计划在今年晚些时候更新其几款下一代CAR-T产品候选者，这可能会进一步推动CRISPR的股价上涨[5] Eli Lilly - Eli Lilly的股价在过去12个月内飙升了近75%，主要得益于其肥胖症药物Zepbound和糖尿病药物Mounjaro的成功[7] - Lilly的其他主要增长驱动因素包括乳腺癌药物Verzenio、治疗糖尿病、心力衰竭和慢性肾脏疾病的Jardiance，以及自身免疫疾病药物Olumiant[10] - Lilly即将在2024年第一季度获得FDA对早期症状阿尔茨海默病治疗药物donanemab的批准决定，分析师认为该药物到2026年的年销售额可能达到60亿美元[12] Novo Nordisk - Novo Nordisk是一家在2023年表现出色的药品公司，其抗肥胖市场前景广阔，而且在其他领域也有不少药物研发进展[13] - Novo Nordisk的长期前景看好，投资者可以安心持有该股票[18]

Zscaler公司业绩 - Zscaler在Q1财年实现了40%的年度收入增长，显示了公司具有强大的市场存在和有效的业务策略[4] - 公司连续13个季度保持“60规则”，展示了在管理费用的同时扩大收入的能力[4] - Zscaler在推动更广泛的平台采用方面处于领先地位，客户购买多个产品支柱，反映了其产品的深度和多样性[5]

Casgevy疗法 - FDA批准了Vertex Pharmaceuticals和CRISPR Therapeutics的Casgevy疗法，用于治疗依赖输血的β地中海贫血[1] - Casgevy是利用CRISPR基因编辑技术治疗严重血液疾病的疗法[5] CRISPR技术 - CRISPR技术被视为医学治疗领域的一个激动人心的前沿，能够精确和准确地改变DNA以治疗一系列疾病[9] - Emmanuelle Charpentier和Jennifer Doudna因发现CRISPR工具而获得了2020年的诺贝尔奖[9]

CRISPR Therapeutics与Vertex Pharmaceuticals合作 - CRISPR Therapeutics宣布美国FDA批准CASGEVY™用于治疗输血依赖性β地中海贫血(TDT)[2] - CASGEVY™是一种CRISPR/Cas9基因编辑细胞疗法，通过编辑患者自身的造血干细胞，在BCL11A基因的红细胞特异性增强子区域引入精确的双链断裂，从而产生高水平的胎儿血红蛋白(HbF)，已被证明可以减少或消除SCD患者的疼痛性危象(VOCs)和TDT患者的输血需求[5] - Vertex负责全球开发、制造和商业化exa-cel，并与CRISPR Therapeutics在全球范围内以60/40的比例分担项目成本和利润[7]

Shares of CRISPR Therapeutics (CRSP -0.91%) climbed 54% in 2023, according to data provided by S&P Global Market Intelligence. The biotech company is developing a number of promising gene-therapy treatments for serious illnesses, but it doesn't currently have any products for sale on the market.CRISPR Therapeutics passed multiple important milestones last year, and the stock moved higher when that news was released. The company is navigating the tricky and expensive regulatory-approval process for its first ...